Literature DB >> 16950012

Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries.

Matti Lehtinen1, Rolando Herrero, Philippe Mayaud, Ruanne Barnabas, Joakim Dillner, Jorma Paavonen, Peter G Smith.   

Abstract

We review studies of the implementation of human papillomavirus (HPV) vaccination programmes in developed and developing countries. The review spans the period from establishment of long-term vaccine efficacy follow-up studies, operational research on issues of vaccine preparedness, and relevant predictive modelling studies during the pre-licensure phase to plans of phase IV effectiveness trials, forms of epidemiological surveillance, and further operational research in the post-licensure phase. Much of the research is already ongoing. Depending on the results of the planned immuno bridging studies among HIV-negative and HIV-positive women, further phase III and/or phase IV trials may be warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16950012     DOI: 10.1016/j.vaccine.2006.05.109

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Re: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Authors:  Noel T Brewer; Paul L Reiter
Journal:  J Natl Cancer Inst       Date:  2010-09-01       Impact factor: 13.506

Review 2.  Human papillomavirus vaccine and cervical cancer prevention.

Authors:  Ana Oaknin; Ma Pilar Barretina
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

3.  Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role.

Authors:  Mona Saraiya; Marc T Goodman; S Deblina Datta; Vivien W Chen; Phyllis A Wingo
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

4.  The future of vaccines for cervical cancer.

Authors:  Warner K Huh; Richard B S Roden
Journal:  Gynecol Oncol       Date:  2008-05       Impact factor: 5.482

Review 5.  An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.

Authors:  John T Schiller; Xavier Castellsagué; Luisa L Villa; Allan Hildesheim
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

Review 6.  Clinical trials of human papillomavirus vaccines and beyond.

Authors:  Matti Lehtinen; Joakim Dillner
Journal:  Nat Rev Clin Oncol       Date:  2013-06-04       Impact factor: 66.675

Review 7.  Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

Authors:  Susan J Keam; Diane M Harper
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.

Authors:  Matti Lehtinen; Camilla Lagheden; Tapio Luostarinen; Tiina Eriksson; Dan Apter; Katja Harjula; Marjo Kuortti; Kari Natunen; Johanna Palmroth; Tiina Petäjä; Eero Pukkala; Mari Siitari-Mattila; Frank Struyf; Pekka Nieminen; Jorma Paavonen; Gary Dubin; Joakim Dillner
Journal:  BMJ Open       Date:  2017-08-18       Impact factor: 2.692

9.  Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.

Authors:  Matti Lehtinen; Tiina Eriksson; Dan Apter; Mari Hokkanen; Kari Natunen; Jorma Paavonen; Eero Pukkala; Maria-Genalin Angelo; Julia Zima; Marie-Pierre David; Sanjoy Datta; Dan Bi; Frank Struyf; Gary Dubin
Journal:  Hum Vaccin Immunother       Date:  2016-12       Impact factor: 3.452

10.  Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania.

Authors:  Joelle Brown; Kathy Baisley; Bazil Kavishe; John Changalucha; Aura Andreasen; Philippe Mayaud; Balthazar Gumodoka; Saidi Kapiga; Richard Hayes; Deborah Watson-Jones
Journal:  Vaccine       Date:  2013-11-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.